Brind.
  1. FDA granted RMAT and Fast Track designations to Lyell Immunopharma.

LYL314, a next-generation CAR T-cell therapy, was identified as a product of Lyell Immunopharma.

1 report, 1 independent Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

LYL314, a next-generation CAR T-cell therapy, was identified as a product of Lyell Immunopharma.

Who's involved

What this event is mainly about
Lyell Immunopharma (United States)

Keep exploring

Part of

FDA granted RMAT and Fast Track designations to Lyell Immunopharma. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 Presented positive new clinical data demonstrating high rates of durable complete responses from the P